Free Trial

Pfizer/BioNTech Begins Omicron Vaccine Testing, CEO Hopes Ready By March

GLOBAL

Pfizer and BioNTech have announced that they have begun clinical trials on a vaccine specifically intended to combat the Omicron COVID variant. Pfizer CEO Albert Bourla stated that his firm hoped that the vaccine would be finalised by March.

  • While the symptoms of the Omicron variant are largely mild, there are concerns that a mutation of Omicron could result in increased virility with the same heightened transmissibility compared to the Delta variant. An effective vaccine developed beforehand could act as a crucial breaker against this scenario.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.